Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

 Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

Innovate and Massachusetts General Hospital Collaborates to Develop Larazotide for Alcoholic Liver Disease

Shots:

  • The collaboration is focused on development of Larazotide for Alcoholic Liver Diseases (ALD), including severe alcoholic hepatitis
  • Innovate will conduct an investor update on 17 Dec, 2018 for Larazotide, in celiac disease clinical program and NASH development strategy
  • Larazotide (INN-202) is a synthetic eight amino acid peptide drug, completed P-II trial and expected to initiate P-III in H1’19 for celiac disease (previously planned to conduct in H2’18)

Click here to read full press release/ article | Ref: Innovate Pharmaceuticals | Image: Contract Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post